About Us

Haus Bioceuticals is a specialty pharmaceutical company focused on the R&D and commercialization of technologies created from clinically-active botanical extracts (bioceuticals). Haus' mission is to develop natural medicines using an evidenced-based approach. Haus’s highly integrated R&D team is comprised of multidisciplinary experts in the fields of naturopathic and allopathic medicine, immunology, and inflammatory biology, and early-stage brand development and commercialization. Haus utilizes state of the art laboratories for lead compound identification, mechanism of action studies, and preclinical assessments. In addition, Haus has an active clinical trial program to identify indications and to quantify efficacy and safety profiles relative to current standards of care. Clinically active botanicals are put through the same rigorous development process as pharmaceutical medicines, bridging the worlds of pharmacologic and naturopathic medicine. This is a unique approach, a third path, where the full potential and mechanisms of action of these natural safe and effective anti-inflammatory treatments is being understood and harnessed in an evidenced-based manner for the first time.

Technologies appropriate for the OTC space are developed into proto-brands by crowdsourcing consumer’s requirements on the largest online commercial channel (Amazon.com) and social media advertising, which is further supported by bioceutical-specific regulatory strategies. Ultimately, technologies and proto-brands are licensed to leading channel partners in the consumer products and professional spaces. In addition to “in-haus” programs, Haus establishes co-development partnerships with other companies.

Contact Us

Meet the Founders

Michael Centola headshot

Dr. Michael Centola

Dr. Centola, Ph.D., is the co-founder, Chief Executive Officer, and Chief Scientific Officer at Haus Bioceuticals. He is an inflammatory disease expert. At the National Institutes of Health, he created scientific breakthroughs that dramatically improved outcomes of a once deadly inflammatory disease. At Haus, his understanding of inflammatory disease helped craft natural products using the same rigorous testing as pharmaceutical medicines. His pioneering work enabled the creation of treatments with unprecedented efficacy and safety.

Philip Alex headshot

Dr. Philip Alex

Dr. Alex, M.D. Ph.D., is the co-founder and Chief Medical Officer of Haus Bioceuticals. Dr. Alex is expert in identifying inflammatory disease mechanisms using a combined laboratory and clinical research approach. His pioneering studies unlocked key insights and novel therapies for inflammatory diseases like rheumatoid arthritis, Crohn’s disease and ulcerative colitis. Dr. Alex’s rigorous R&D experience helped shape Haus’ culture. His focus on defining key inflammatory mechanisms provides a bridge between the world of natural and traditional medicine.